Hims & Hers Health Inc

Hims & Hers Health Inc

Health CareHealth Care Providers
  • Price (USD)9.46
  • Today's Change-0.235 / -2.43%
  • Shares traded1.78m
  • 1 Year change+79.07%
  • Beta0.4896
Data delayed at least 15 minutes, as of Mar 23 2023 18:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hims & Hers Health, Inc. is a consumer-first platform focused on providing personalized health and wellness experiences to consumers. The Company's digital platform enables access to treatments for a range of conditions, including those related to sexual health, hair loss, dermatology, mental health and primary care. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate. The prescriptions are fulfilled online through licensed pharmacies on a subscription basis. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. The Company's products include shampoo, conditioner, biotin gummies, anti-aging cream, vitamin c serum, acne cream and moisturizer. Its products are sold in tens of thousands of retail locations in the United States.

  • Revenue in USD (TTM)526.92m
  • Net income in USD-65.68m
  • Incorporated2021
  • Employees651.00
  • Location
    Hims & Hers Health Inc2269 Chestnut St, #523SAN FRANCISCO 94123United StatesUSA
  • Phone+1 (415) 851-0195
  • Fax+1 (302) 655-5049
  • Websitehttps://www.forhims.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Relay Therapeutics Inc1.38m-290.51m1.89bn327.00--1.99--1,369.42-2.60-2.600.01237.850.0013--0.27194,223.24-27.56---28.76-------21,036.13------0.00---54.41--20.16------
Myriad Genetics, Inc.678.40m-112.00m1.90bn2.60k--2.14--2.80-1.39-1.398.4210.910.538511.417.03260,923.10-8.89---10.29--70.22---16.51--1.85-206.170.00---1.77---357.14------
Krystal Biotech Inc0.00-139.98m1.92bn210.00--3.68-----5.50-5.500.0020.270.00----0.00-23.63-17.34-24.77-18.06------------0.00-------101.20--202.26--
Supernus Pharmaceuticals Inc667.24m60.71m2.00bn612.0035.132.2513.582.991.041.0411.1216.330.39350.98284.241,090,258.003.587.275.089.1186.9390.409.1018.110.9341--0.312--15.0917.1613.64-1.95-27.30--
Amylyx Pharmaceuticals Inc22.23m-198.38m2.02bn262.00--5.91--90.82-3.43-3.430.38025.120.0894----84,847.33-79.82---91.62--86.54---892.38--7.99--0.00--7,700.00---125.60------
Hims & Hers Health Inc526.92m-65.68m2.09bn651.00--6.71--3.97-0.3214-0.32142.581.501.346.73154.79809,394.80-16.69---19.91--77.57---12.46--4.07--0.00--93.81--38.99------
Xenon Pharmaceuticals Inc9.43m-124.94m2.11bn203.00--2.90--223.58-1.95-1.950.151511.530.0142--5.0346,472.91-18.91-21.60-19.45-23.05-----1,328.95-462.39----0.00---48.8397.87-62.07--55.83--
Immunovant Inc0.00-198.70m2.11bn124.00--5.05-----1.65-1.650.003.210.00----0.00-39.76---43.11--------------0.00-------45.89------
BridgeBio Pharma Inc77.65m-481.18m2.16bn392.00------27.87-3.26-3.260.5265-8.330.0949----198,081.60-59.25-64.11-71.02-78.4595.5895.39-624.17-1,037.16----3.69--11.38--14.46--68.60--
Provention Bio Inc2.80m-106.12m2.18bn82.00--14.39--778.86-1.56-1.560.04081.660.0159----34,134.14-60.33-79.68-69.39-88.17-----3,791.21-20,925.40----0.1386-------16.08------
TG Therapeutics Inc2.78m-198.34m2.18bn226.00--37.28--784.39-1.47-1.470.02060.40020.0097--4.0112,318.58-69.20-83.88-87.25-108.4890.48---7,124.10-11,804.33---18.920.5484---58.3678.8043.02--44.40--
AbCellera Biologics Inc485.43m158.52m2.19bn495.0015.321.7711.764.520.49730.49731.624.300.3395--1.03980,658.6011.09--12.10------32.66--8.65--0.00--29.38--3.29------
Ventyx Biosciences Inc0.00-90.98m2.25bn31.00--5.86-----1.79-1.790.006.770.00----0.00-31.97---34.88--------------0.00-------202.75------
Revolution Medicines Inc35.38m-248.71m2.27bn246.00--2.82--64.08-3.10-3.100.4397.570.0457--6.67143,821.10-32.09-30.02-34.84-33.44-----702.95-355.93----0.00--20.38---32.93--47.01--
Corcept Therapeutics Incorporated401.86m101.42m2.29bn299.0024.285.5522.445.710.87510.87513.473.830.7980.971313.701,344,007.0020.1423.0822.8625.7598.6698.3925.2429.156.80--
Data as of Mar 23 2023. Currency figures normalised to Hims & Hers Health Inc's reporting currency: US Dollar USD

Institutional shareholders

20.23%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202211.03m5.53%
BlackRock Fund Advisorsas of 31 Dec 20228.00m4.01%
Marshall Wace LLPas of 31 Dec 20224.49m2.25%
Millennium Management LLCas of 31 Dec 20223.52m1.77%
Oaktree Capital Management LPas of 31 Dec 20223.27m1.64%
SSgA Funds Management, Inc.as of 31 Dec 20222.94m1.48%
Geode Capital Management LLCas of 31 Dec 20222.19m1.10%
Franklin Advisers, Inc.as of 31 Dec 20221.79m0.90%
Canada Pension Plan Investment Boardas of 31 Dec 20221.58m0.79%
Renaissance Technologies LLCas of 31 Dec 20221.51m0.76%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.